Financial Comparison: Imprivata (IMPR) & Its Competitors

Imprivata (NYSE: IMPR) is one of 97 public companies in the “Enterprise Software” industry, but how does it compare to its competitors? We will compare Imprivata to related businesses based on the strength of its analyst recommendations, valuation, dividends, earnings, risk, profitability and institutional ownership.

Earnings and Valuation

This table compares Imprivata and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Imprivata N/A N/A -20.71
Imprivata Competitors $1.27 billion $348.15 million 37.17

Imprivata’s competitors have higher revenue and earnings than Imprivata. Imprivata is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Imprivata and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imprivata 0 0 0 0 N/A
Imprivata Competitors 343 2044 3882 107 2.59

As a group, “Enterprise Software” companies have a potential upside of 2.70%. Given Imprivata’s competitors higher probable upside, analysts clearly believe Imprivata has less favorable growth aspects than its competitors.

Volatility & Risk

Imprivata has a beta of -1.21, indicating that its stock price is 221% less volatile than the S&P 500. Comparatively, Imprivata’s competitors have a beta of 1.13, indicating that their average stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Imprivata and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Imprivata -17.22% -58.85% -22.17%
Imprivata Competitors -25.34% -211.44% -8.21%

Insider & Institutional Ownership

59.3% of Imprivata shares are owned by institutional investors. Comparatively, 59.2% of shares of all “Enterprise Software” companies are owned by institutional investors. 40.2% of Imprivata shares are owned by insiders. Comparatively, 23.4% of shares of all “Enterprise Software” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

About Imprivata

Imprivata, Inc. (Imprivata) is a United States-based healthcare information technology security company. The Company enables healthcare organizations to access, communicate and transact patient information securely. The Company offers Imprivata OneSign, Imprivata Cortext, Imprivata Confirm ID and Imprivata PatientSecure. Imprivata OneSign provides single sign-on, authentication management and virtual desktop roaming, enabling No Click Access to clinical applications and patient information, anytime, anywhere and from any device. Imprivata Cortext enables clinicians to collaborate across care teams and organizations. Imprivata Confirm ID is an identity and two-factor authentication platform for remote access, electronic prescriptions for controlled substances (EPCS), medical device access and other clinical authentication workflows. Imprivata PatientSecure is a patient identification solution that uses palm vein recognition biometrics to identify patients at any point of entry to care.

Receive News & Ratings for Imprivata Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprivata Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply